002737 葵花药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,683,984-43.24%3,377,0485,700,2875,094,5114,460,900
减:营业总成本1,747,427-25.78%2,865,4374,496,1214,055,8403,647,406
    其中:营业成本1,049,912-25.92%1,860,9752,491,5592,152,4571,817,085
               财务费用(3,924)-81.94%(23,099)(31,963)(11,157)(9,914)
               资产减值损失(6,840)87.40%(56,930)(978)(29,358)(32,413)
公允价值变动收益5,085-242.31%(12,985)(16,388)(19,307)2,668
投资收益19,67653.89%24,93246,9649,39023,689
    其中:对联营企业和合营企业的投资收益(1,189)-9.11%(2,225)(2,506)(1,332)(744)
营业利润2,349-99.68%636,2431,366,8261,084,990885,203
利润总额(6,235)-100.84%634,4881,354,7701,081,105894,514
减:所得税费用39,680-71.42%131,756189,831171,370132,165
净利润(45,914)-107.58%502,7321,164,939909,735762,350
减:非控股权益(12,376)-166.26%10,68645,79742,51357,612
股东净利润(33,539)-105.72%492,0451,119,142867,222704,738

市场价值指针
每股收益 (元) *-0.060-106.00%0.8401.9201.4801.210
每股派息 (元) *----0.5001.5001.0000.700
每股净资产 (元) *6.939-9.53%7.4998.1577.2006.352
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容